Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
There are two academic institutions directly subordinate to the CMC, the National Defense University and the National University of Defense Technology, and they are considered the two top military education institutions in China. There are also 35 institutions affiliated to the PLA's branches and arms, and 7 institutions affiliated to the People's Armed Police.
=== Conformational selection hypothesis === This model suggests that enzymes exist in a variety of conformations, only some of which are capable of binding to a substrate. When a substrate is bound to the protein, the equilibrium in the conformational ensemble shifts towards those able to bind ligands (as enzymes with bound substrates are removed from the equilibrium between the free conformations).
UK-447841 is a neprilysin inhibitor (NEPI) which was under development for the treatment of female sexual dysfunction. It is taken as-needed orally. The drug is intended to work by inhibiting vasoactive intestinal peptide (VIP) hydrolysis by neprilysin (NEP). However, neprilysin is also involved in the metabolism of more than 50 other hormones and neuropeptides, for instance oxytocin among others. UK-447841 was under development by Pfizer. It reached phase 2 clinical trials prior to the discontinuation of its development in 2008.
=== Spoofing jammers, jitter === A second jamming system was eventually activated at Cap Gris Nez in September, using a system that triggered its signal in response to the reception of a pulse from CH. This meant that the system responded to the CH station even if it moved its time slot. These systems, known as Garmisch-Partenkirchen, were used during Operation Donnerkeil in 1941. Further improvements to the basic concept allowed multiple returns to be generated, appearing like multiple aircraft on the CH display. Although these new jammers were relatively sophisticated, CH operators quickly adapted to them by periodically changing the pulse repetition frequency (PRF) of their station's transmitter. This caused the synchronized jamming signals to briefly go out of synch with the station, and the blips from the jammers would "jitter" on the screen, allowing them to be visually distinguished. The "Intentional Jitter Anti-Jamming Unit", IJAJ, performed this automatically and randomly, making it impossible for the German jammers to match the changes. Another upgrade helped reject unsynchronized pulses, supplanting the two-layer display. This device, the "Anti-Jamming Black-Out" unit, AJBO, fed the Y-axis signal into a delay and then into the brightness control of the CRT. Short pulses that appeared and disappeared were muted, disappearing from the display. Similar techniques using acoustic delay lines, both for jamming reduction and filtering out noise, became common on many radar units during the war.
Attempts to contact by mail in the late 1890s failed. United Brothers of Friendship - Founded August 1, 1861, by young local students in day or night schools. In 1868, on the advice of their teacher, W.H. Gibson, the society reorganized. Many chapters were formed in Kentucky, and a statewide Grand Lodge was formed in 1871. After establishing chapters outside Kentucky a National Grand Lodge was formed. W.H. Gibson served as the first State Grand Master for five years and as National Grand Master for four years. Unofficial female auxiliaries were called the Sisters of Friendship until 1878 when the organization formed the official Sisters of the Mysterious Ten, organized in local Temples. In 1878 the Order had about 4,000 members. That was the year they decided to establish another auxiliary, the Knights of Friendship, based on the story of David and Jonathan. In 1892 the UBF had 100,000 members in 19 states and 2 territories with 30,000 in Missouri alone. It was known to be active in Kentucky, Missouri, Arkansas, Louisiana, Texas, Mississippi, Alabama, Tennessee, West Virginia, Virginia, the District of Columbia, Pennsylvania, New York, New Jersey, Michigan, Kansas, Colorado, Washington, Canada, the West Indies and Africa. While predominantly black, the order had white members. There was evidence that the Grand United Order of Odd Fellows had something to do with its founding. United Knights and Daughters of America - Headquartered in St. Louis, Missouri. Reportedly had many members in the Midwest. Attempts to contact the order in 1923 were unsuccessful.
Sources: en.wikipedia.org
=== Direct immunofluorescence testing === The presence of Immunoglobulin G, A, or M in the epidermis is normal. Detection in other locations such as intercellular and areas below the epidermis (subepidermal), as well as along the dermoepidermal junction (area that joins the epidermis and dermis), suggests paraneoplastic pemphigus.
=== Anti-atherosclerotic and anti-inflammatory effects === 1-MNA exhibits anti-atherosclerotic and anti-inflammatory properties by improving the prostacyclin- and NO-dependent secretory function of the vascular endothelium, inhibiting platelet activation, reducing inflammation within atherosclerotic plaques, and lowering systemic inflammation and TNF-α levels. The anti-inflammatory effects of 1-MNA are linked to its ability to stimulate endogenous PGI2 secretion and reduce IL-4 and TNF-α levels. These effects are mediated by endothelial mechanisms rather than a direct impact on immune cell function, ensuring that the body's immune response is not weakened.
Other memberships include the African Development Bank, East African Community, Group of 77, Intergovernmental Authority on Development, International Bank for Reconstruction and Development, International Civil Aviation Organization, International Development Association, International Finance Corporation, Non-Aligned Movement, World Federation of Trade Unions and World Meteorological Organization.
The cold surges on the eastern slopes of the Rocky Mountains, Iceland, New Zealand, and eastern Asia differ from the cold air damming east of the Appalachians due to the wider mountain ranges, sloping terrain, and lack of an eastern body of warm water.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.